Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets remain buoyant
Thu, 28 Nov 01:30 pm

After a firm opening, Indian share markets continued to trade well above the dotted line in the post-noon trading session. All the sectoral indices are trading in the green with realty, capital goods and power stocks being the biggest gainers.

BSE-Sensex is up 133 points and NSE-Nifty is trading 42 points up. BSE Mid Cap is trading up 0.8% and BSE Small Cap index is trading up 1%. The rupee is trading at 62.4 to the US dollar.

All the automobile stocks are trading in the green with Eicher Motors and Ashok Leyland being the major gainers. As per a leading financial daily, Ashok Leyland has launched intermediate commercial range of vehicle 'Boss' in Andhra Pradesh market. The new range will be launched across the country in a phased manner after operations are consolidated in the southern and western regions. Ashok Leyland wants to increase its presence in the rapidly growing intermediate range of commercial vehicles that have carrying capacity of 8 to 16 tonnes. Currently the company has a single offering in this segment and plans to acquire a bigger share through the launch of Boss for haulage in 9.6, 11.9 and 12.9 tonnes. The Boss range is manufactured in the company's Pantnagar facility in Uttarakhand. Ashok Leyland's stock is currently trading up by 3.2%.

Most of the Indian pharma stocks are trading in green with Indoco Remedies and Glenmark Pharmaceuticals witnessing maximum buying. Recently, Wockhardt Ltd announced that the company's second facility has also received import alert on its Chikalthana facility. It is important to note that company's key product Metropolol succinate was also manufactured in this facility. The ban on this product will be quite negative for the company. This was an important contributor to the company's US revenues. Company had around 20% market share in this product. There are just 4-5 players who have launched this product. By nature this product has high entry barriers and thus better margins. Among these 4-5 players, even <>Dr Reddy's sells the generics of this drug in the US market. It is likely that the ban on Wockhardt's facility might impact its market share with Dr Reddy's and other players expected to gain. In our view, Dr Reddy currently has 12% market share in Metropolol succinate and might gain some share from Wockhardt's exit.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.